Merck Sharp + Dohme Corp.

Msd R&d (China) Co., Ltd.

Msd R&d Co., Ltd.

Bart Harper

Richard Berger

Scott D Edmondson

Dong-Ming Shen

Meng Yang

Cheng Zhu

Jiayi Xu

Harvey Wendt

Deping Wang

Bing Li

XiaoXia Qian

Liping Wang

Lehua Chang

Nam Fung Kar

Ming Wang

Sunita V Dewnani

Yimin Qian

Amjad Ali

Melissa S Egbertson

Ann E Weber

Jeffrey John Hale

Feroze Ujjainwalla

Ping Liu

Jason M Cox

Songnian Lin

John S Debenham

Shawn P Walsh

Harold B Wood

Gregori J Morriello

Ying-Duo Gao

Helen Y Chen

Dongfang Meng

Santhosh Francis Neelamkavil

Wanying Sun

Ihor E Kopka

Manuel De Lera Ruiz

Yeon-Hee Lim

Eric Mertz

Timothy A Blizzard

Brian T Campbell

Weiguo Liu

Wei Zhou

Stephen D Goble

Christopher Joseph Sinz

Shimin Xu

Dann LeRoy Parker, Jr

Vincent Colandrea

Timothy Allen Blizzard

Hong Li

Deyou Sha

Ting Zhang

Thomas A Bara

Robert Kevin Orr

Libo Xu

Zhiqiang Guo

Zack Zhiqiang Guo

Zhiyong Hu

Tianying Jian

Rui Zhang

Vanessa L Rada

Christopher R Moyes

Jonathan E Wilson

Chris Moyes

Candido Gude

Jane Yang Wu

Louis-Charles Campeau

Timothy A Cernak

Byron Dubois

Yingjian Bo

Greg J Morriello

Vincent J Colandrea

Dong Ming Shen

Harvey R Wendt

Christopher J Sinz

Chris R Moyes

Zack Zhi Qiang Guo

Thomas Bara

Santhosh F Neelamkavil

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors. 

Factor IXa inhibitors

The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia (PDD), and other diseases associated with striatal hypofunction or basal ganglia dysfunction. 

Pyrimidinone amide compounds as PDE2 inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein. 

Factor XIA inhibitors

The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity. 

Isoquinoline derivatives as MGAT2 inhibitors

Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof. 

Pyrimidone carboxamide compounds as PDE2 inhibitors

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of b3-adrenoceptor. 

&#x3b2;3 adrenergic receptor agonists

The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of &#x3b2;3-adrenoceptor. 

Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of &#x3b2;3-adrenoceptor. 

Pyrrolidine derived beta 3 adrenergic receptor agonists

The present invention is directed to novel substituted aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DPP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Growing community of inventors

New York, NY, United States of America

Bart Harper